Advanced Nanomaterials for the Diagnosis and Treatment of Renal Cell Carcinoma

被引:5
|
作者
Ji, Chen [1 ,2 ,3 ]
Li, Junru [1 ,2 ,3 ]
Mei, Junyang [1 ,2 ,3 ]
Su, Weiran [1 ,2 ,3 ]
Dai, Huili [1 ,2 ,3 ]
Li, Fengqin [1 ,2 ,3 ]
Liu, Peifeng [1 ,2 ,3 ]
机构
[1] Shanghai Jiao Tong Univ, RenJi Hosp, Shanghai Canc Inst, Sch Med,State Key Lab Oncogenes & Related Genes, Shanghai 200032, Peoples R China
[2] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Cent Lab, Shanghai 200127, Peoples R China
[3] Shanghai Jiao Tong Univ, RenJi Hosp, Micronano Res & Diag Ctr, Sch Med, Shanghai 200127, Peoples R China
来源
ADVANCED NANOBIOMED RESEARCH | 2023年 / 3卷 / 02期
基金
中国国家自然科学基金;
关键词
diagnosis; drug delivery systems; nanomaterials; renal cell carcinoma; treatments; MESOPOROUS SILICA NANOPARTICLES; IN-VITRO; DRUG-DELIVERY; IMMOBILIZED-TRYPSIN; CANCER; THERAPY; TUMOR; CONTRAST; SIRNA; BIODISTRIBUTION;
D O I
10.1002/anbr.202200079
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Renal cell carcinoma (RCC) is the most common type of kidney cancer. Owing to the high morbidity rate of RCC, there is an urgent need for intensive research on robust materials to diagnose and treat RCC. Nanomaterials have been developed largely in the last three decades because of their numerous advantages, such as high specific surface area, simple surface functionalization, rapid onset of therapeutic action, superior biological activity, and other unique physical-chemical characteristics. Herein, first, various types of nanomaterials used in RCC treatment are introduced, including inorganic nanomaterials, lipid nanomaterials, synthetic polymer nanomaterials, and natural nanomaterials. Second, the different diagnosis and therapeutic mechanisms of nanomaterials in the kidneys are reviewed and these advantages of nanomaterials are highlighted. Furthermore, nanomaterials are investigated for the preclinical and clinical detection and treatment of RCC. Finally, the challenges and outlook of various nanomaterials for RCC diagnostic and treatment are discussed.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Profile of temsirolimus in the treatment of advanced renal cell carcinoma
    Staehler, Michael
    Haseke, Nicolas
    Khoder, Wael
    Stief, Christian G.
    ONCOTARGETS AND THERAPY, 2010, 3 : 191 - 196
  • [32] Pazopanib for the Treatment of Patients with Advanced Renal Cell Carcinoma
    Lang, Joshua M.
    Harrison, Michael R.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2010, 4 : 95 - 105
  • [33] TREATMENT OF PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA
    AULITZKY, WE
    HUBER, C
    ONKOLOGIE, 1994, 17 (04): : 437 - 437
  • [34] CLINICAL TREATMENT OF ADVANCED RENAL-CELL CARCINOMA
    PANZA, N
    DECESARE, M
    BATTISTA, C
    PACILIO, G
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 1984, 3 (02) : 199 - 209
  • [35] Targeted agents for the treatment of advanced renal cell carcinoma
    Staehler, M
    Rohrmann, K
    Haseke, N
    Stief, CG
    Siebels, M
    CURRENT DRUG TARGETS, 2005, 6 (07) : 835 - 846
  • [36] Targeted agents for the treatment of advanced renal cell carcinoma
    Stadler, WM
    CANCER, 2005, 104 (11) : 2323 - 2333
  • [37] Interdisciplinary recommendations for the treatment of advanced renal cell carcinoma
    Miller, Kurt
    Bergmann, Lothar
    Doehn, Christian
    Gruenwald, Viktor
    Gschwend, Juergen E.
    Ivanyi, Philipp
    Kuczyk, Markus A.
    AKTUELLE UROLOGIE, 2022, 53 (05) : 403 - 415
  • [38] Diagnosis and treatment of clear cell tubulopapillary renal cell carcinoma
    Qiu, Min
    Ma, Lulin
    Lu, Jian
    INTERNATIONAL JOURNAL OF UROLOGY, 2016, 23 : 55 - 55
  • [39] Epidemiology, diagnosis, and surgical treatment of renal cell carcinoma
    Kurosch, M.
    Reiter, M.
    Haferkamp, A.
    ONKOLOGE, 2014, 20 (09): : 899 - 908
  • [40] Diagnosis and Treatment of Renal Cell Carcinoma During Pregnancy
    Xu, Hainan
    Tan, Shutao
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 9423 - 9428